SignalXSignalX

Mineralys Therapeutics, Inc. (MLYS) 8-K Current Report: March 9, 2026

Filed: March 9, 2026
Health Care
Pharmaceutical Preparations
Mineralys Therapeutics, Inc. Overview

Mineralys Therapeutics, Inc. (MLYS) 8-K current report filed with SEC EDGAR on March 9, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

  • Item 7.01: Regulation FD Disclosure
  • Item 8.01: Other Events

Mineralys Therapeutics, Inc. 8-K Mar 9, 2026 Event Analysis

Item 7.01 · Regulation FD Disclosure

  • • FDA accepted NDA for lorundrostat to treat adult hypertension (in combination with other antihypertensive drugs) — key regulatory milestone toward commercialization
  • • NDA acceptance triggers PDUFA date assignment, moving lorundrostat closer to potential approval and market launch
  • • Company simultaneously released topline Phase 2 Explore-OSA trial results, expanding lorundrostat's potential indication pipeline beyond hypertension

Item 8.01 · Other Events

  • • FDA accepted NDA for lorundrostat (hypertension combination therapy); PDUFA action date set for December 22, 2026 — key regulatory catalyst
  • • Phase 2 Explore-OSA trial missed primary endpoint: lorundrostat 50mg failed to show clinically meaningful AHI reduction vs. placebo in obstructive sleep apnea
  • • Strong BP signal in OSA trial: lorundrostat reduced systolic BP by 11.1 mmHg (p<0.0001) vs. 1.0 mmHg placebo; 6.2 mmHg placebo-adjusted reduction in crossover analysis
  • • Clean safety profile in OSA trial: no potassium excursions above 5.5 mmol/L — supports tolerability narrative for core hypertension NDA
  • • Near-term focus shifts entirely to December 2026 FDA decision; OSA miss removes a potential label expansion opportunity but doesn't derail primary indication

Other Mineralys Therapeutics, Inc. 8-K Filings

8-K Mar 12, 2026

Get deeper insights on Mineralys Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.